

NCIC CLINICAL TRIALS GROUP - GI DISEASE SITE COMMITTEE

**PANCREAS
DISEASE ORIENTED GROUP**

AGENDA

OPEN SESSION

Venue: Wren Room, Delta Chelsea Hotel, Toronto

Date: Saturday, April 30th, 2011

Time: 08:00 to 09:15 hrs

Chairs: Dr. Malcolm Moore & Dr. Steve Gallinger

08:00 WELCOME AND INTRODUCTION / MEMBERSHIP UPDATE Dr. M. Moore & Dr. S. Gallinger

08:15 – 09:00 TRIALS/CONCEPTS IN DEVELOPMENT/PROCESS

NEOADJUVANT

ADJUVANT

ACCORD 24: Randomized multicenter phase III comparison of adjuvant chemotherapy with gemcitabine versus a combination of 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (mFOLFIRINOX) in patients with resected pancreatic adenocarcinoma

METASTATIC/ADVANCED

PA.5 (GERCOR LAP.07) - Randomized multicentre phase III study in patients with locally advanced adenocarcinoma of the pancreas: gemcitabine with or without chemoradiotherapy and with or without erlotinib

HENT1 - A multicentre, randomized, open label phase III study of gemcitabine versus FOLFOX in the first line setting for metastatic pancreatic cancer patients using upfront human equilibrative nucleoside transporter 1 (hENT1) biomarker testing

Dr. J. Spratlin

IND

09:00 – 09:15 INTERGROUP TASK FORCE UPDATE

CALGB 81003 – Concept: Phase IB then randomized Phase II trial of FOLFIRINOX + [AMG-479 vs placebo]

ECOG – Neo-adjuvant proposal for GTX vs FOLFIRINOX for borderline resectable pancreas

09:15 CLOSING REMARKS